See All Slides - tctmd.com

Slides

Presentation TCT 2015

Should MRI Be the New Gold Standard for Mitral Imaging and MR Quantification?

Presenter: Robert J. Siegel, Neil J. Weissman, Paul A. Grayburn

October 11, 2015

Presentation TCT 2015

Strategy Trials vs Device/Drug Comparisons: Important Considerations

Presenter: Stuart J. Pocock, Jan Tijssen, David J. Cohen

October 11, 2015

Presentation TCT 2015

Which Aortic Stenosis Patients Are Definitely NOT TAVR Candidates in 2015?

Presenter: Martin B. Leon, Neil E. Moat, Thomas Walther

October 11, 2015

Presentation TCT 2015

Debate: What Is the Ideal Duration of DAPT After DES? Shorter Is Best (for Most)!

Presenter: John A. Bittl, E. Magnus Ohman, Hyeon-Cheol Gwon

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Slow Down, Excess Bleeding, and No Mortality Benefit? Primum Non Nocere and Save Costs!

Presenter: C. Michael Gibson, Marco Valgimigli, Tullio Palmerini

October 11, 2015

Presentation TCT 2015

Emerging Role of CT for Assessment of Mitral Valve Anatomy and Dysfunction

Presenter: Robert J. Siegel, Neil J. Weissman, Jonathon A. Leipsic

October 11, 2015

Presentation TCT 2015

What Are the Indications for TAVR in 2015? According to Real-World Clinical Practice

Presenter: Martin B. Leon, Neil E. Moat, Axel Linke

October 11, 2015

Presentation TCT 2015

My Nightmare Mitral Valve Case

Presenter: Mohamed Chettibi, Ziyad M. Hijazi

October 11, 2015

Presentation TCT 2015

Amplatzer Cardiac Plug (ACP): Updated Results and Future Directions

Presenter: Reda Ibrahim, Matthew J. Price

October 11, 2015

Presentation TCT 2015

Biomimetic Stents: Rationale and Current Clinical Results

Presenter: Prakash Krishnan, Mahmood K. Razavi, Eric J. Dippel

October 11, 2015

Advertisement

Slides

Should MRI Be the New Gold Standard for Mitral Imaging and MR Quantification?

Strategy Trials vs Device/Drug Comparisons: Important Considerations

Which Aortic Stenosis Patients Are Definitely NOT TAVR Candidates in 2015?

Debate: What Is the Ideal Duration of DAPT After DES? Shorter Is Best (for Most)!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Slow Down, Excess Bleeding, and No Mortality Benefit? Primum Non Nocere and Save Costs!

Emerging Role of CT for Assessment of Mitral Valve Anatomy and Dysfunction

What Are the Indications for TAVR in 2015? According to Real-World Clinical Practice

My Nightmare Mitral Valve Case

Amplatzer Cardiac Plug (ACP): Updated Results and Future Directions

Biomimetic Stents: Rationale and Current Clinical Results

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content